BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Price & Overview
NASDAQ:BCYC • US0887861088
Current stock price
The current stock price of BCYC is 4.9 USD. Today BCYC is up by 0.2%. In the past month the price decreased by -8.92%. In the past year, price decreased by -26.87%.
BCYC Key Statistics
- Market Cap
- 339.903M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.16
- Dividend Yield
- N/A
BCYC Stock Performance
BCYC Stock Chart
BCYC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BCYC. When comparing the yearly performance of all stocks, BCYC is a bad performer in the overall market: 87.88% of all stocks are doing better.
BCYC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCYC. The financial health of BCYC is average, but there are quite some concerns on its profitability.
BCYC Earnings
On March 17, 2026 BCYC reported an EPS of -0.29 and a revenue of 47.95M. The company beat EPS expectations (69.66% surprise) and beat revenue expectations (564.66% surprise).
BCYC Forecast & Estimates
19 analysts have analysed BCYC and the average price target is 13.17 USD. This implies a price increase of 168.72% is expected in the next year compared to the current price of 4.9.
For the next year, analysts expect an EPS growth of -20.36% and a revenue growth 5.39% for BCYC
BCYC Groups
Sector & Classification
BCYC Financial Highlights
Over the last trailing twelve months BCYC reported a non-GAAP Earnings per Share(EPS) of -3.16. The EPS decreased by -7.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.51% | ||
| ROE | -35.9% | ||
| Debt/Equity | 0 |
BCYC Ownership
BCYC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.91 | 364.897B | ||
| AMGN | AMGEN INC | 14.9 | 183.284B | ||
| GILD | GILEAD SCIENCES INC | 15.7 | 172.309B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.28 | 109.705B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.26 | 80.376B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.82 | 42.375B | ||
| INSM | INSMED INC | N/A | 35.141B | ||
| NTRA | NATERA INC | N/A | 29.66B | ||
| BIIB | BIOGEN INC | 10.92 | 25.773B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.94 | 24.795B | ||
| MRNA | MODERNA INC | N/A | 19.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.082B | ||
| INCY | INCYTE CORP | 12.23 | 18.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCYC
Company Profile
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Company Info
IPO: 2019-05-23
BICYCLE THERAPEUTICS PLC-ADR
Blocks A & B, Portway Building, Granta Park, Great Abington
Cambridge CAMBRIDGESHIRE CB22 3AT GB
CEO: Kevin Lee
Employees: 305
Phone: 11441223261503
BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ
What does BCYC do?
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Can you provide the latest stock price for BICYCLE THERAPEUTICS PLC-ADR?
The current stock price of BCYC is 4.9 USD. The price increased by 0.2% in the last trading session.
Does BICYCLE THERAPEUTICS PLC-ADR pay dividends?
BCYC does not pay a dividend.
What is the ChartMill rating of BICYCLE THERAPEUTICS PLC-ADR stock?
BCYC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of BCYC stock?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) operates in the Health Care sector and the Biotechnology industry.
What is the Short Interest ratio of BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?
The outstanding short interest for BICYCLE THERAPEUTICS PLC-ADR (BCYC) is 4.6% of its float.